Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)
Clinical trial NCT01015352 · COMPLETED
Trial details
- NCT number
- NCT01015352
- Sponsor
- Groupe Francophone des Myelodysplasies
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-01
- Primary completion
- 2014-03-01
- Enrollment
- 98
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.